<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="eee53caf-0710-4e75-9663-d925f8378d8d"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold"> Prednisolone Acetate Ophthalmic Suspension USP, 1% </content>
      <br/>
      <content styleCode="bold">
         <br/>
      </content>
      <content styleCode="bold"> STERILE </content>
      <br/>
      <content styleCode="bold">
         <br/>
      </content>
      <content styleCode="bold"> Rx Only </content>
   </title>
   <effectiveTime value="20250424"/>
   <setId root="f0e1b691-73ff-49ee-8a3c-71769b284ab8"/>
   <versionNumber value="1"/>
   <author>
      <assignedEntity>
         <representedOrganization>
            <id extension="830016429" root="1.3.6.1.4.1.519.1"/>
            <name>A-S Medication Solutions</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="830016429" root="1.3.6.1.4.1.519.1"/>
                        <name>A-S Medication Solutions</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" displayName="RELABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50090-7539" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="451d73eb-9c9d-469a-9240-cc4a4c45bd33"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250401"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50090-7539" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>PREDNISOLONE ACETATE<suffix/>
                        </name>
                        <formCode code="C60995" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUSPENSION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>prednisolone acetate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="70748-332" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="10" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8B2807733D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PREDNISOLONE ACETATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9PHQ9Y1OLM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PREDNISOLONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEG-20 SORBITAN OLEATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="TZX5469Z6I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BISULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5EYA69XGAT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2906 (4000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="50090-7539-0" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250422"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216935" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20241011"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="976aeda1-8cf4-4745-86e8-6bc4cc9a92e2"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Prednisolone acetate ophthalmic suspension USP, 1% is a sterile, topical anti-inflammatory agent for ophthalmic use. Its chemical name is 11ß,17, 21-Trihydroxypregna-1,4-diene-3, 20-dione 21-acetate and it has the following structure: </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Each mL of prednisolone acetate ophthalmic suspension USP contains: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active:</content> prednisolone acetate (micronized) 1% </paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive:</content> benzalkonium chloride as preservative, boric acid, edetate disodium, hypromellose, polysorbate 80, sodium bisulfite, sodium chloride, sodium citrate and water for injection. </paragraph>
                  <paragraph>The pH during its shelf life ranges from 5.0 to 6.0.</paragraph>
               </text>
               <effectiveTime value="20250401"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="f91d91ab-9100-4c26-967b-7d7efc290dc9-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID5">
               <id root="8e4ed4ec-05e2-432c-a902-96bf07a3a992"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammatory potency of hydrocortisone. Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation.</paragraph>
               </text>
               <effectiveTime value="20220405"/>
            </section>
         </component>
         <component>
            <section ID="ID7">
               <id root="f6dd1929-0d09-46dd-8ad3-d59e1ba057ca"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Prednisolone acetate ophthalmic suspension is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.</paragraph>
               </text>
               <effectiveTime value="20220405"/>
            </section>
         </component>
         <component>
            <section ID="ID9">
               <id root="49b36fe6-2c5a-4bb9-9c9f-7c5647c7992d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Prednisolone acetate ophthalmic suspension is contraindicated in acute untreated purulent ocular infections, in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. </paragraph>
                  <paragraph>Prednisolone acetate ophthalmic suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.</paragraph>
               </text>
               <effectiveTime value="20220405"/>
            </section>
         </component>
         <component>
            <section ID="ID11">
               <id root="37017de1-7186-4e6b-b84c-a740e8790f85"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Prolonged use of corticosteroids may result in posterior subcapsular cataract formation and may increase intraocular pressure in susceptible individuals, resulting in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections. </paragraph>
                  <paragraph>If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently.</paragraph>
                  <paragraph>Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation.</paragraph>
                  <paragraph>Acute purulent infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication. </paragraph>
                  <paragraph> </paragraph>
                  <paragraph>The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.</paragraph>
                  <paragraph>Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.</paragraph>
                  <paragraph>Prednisolone acetate ophthalmic suspension contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.</paragraph>
               </text>
               <effectiveTime value="20220405"/>
            </section>
         </component>
         <component>
            <section ID="ID13">
               <id root="ee1b06db-0fe6-4014-9a13-cb7dc95bc103"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20220405"/>
               <component>
                  <section ID="ID14">
                     <id root="10d4a0f0-2091-41ae-a014-a0202d0d5470"/>
                     <title>General</title>
                     <text>
                        <paragraph>The initial prescription and renewal of the medication order beyond 20 milliliters of prednisolone acetate ophthalmic suspension should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.</paragraph>
                        <paragraph>As fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid applications, fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate.</paragraph>
                     </text>
                     <effectiveTime value="20220405"/>
                  </section>
               </component>
               <component>
                  <section ID="ID16">
                     <id root="42d77710-8092-4c96-9c9b-cd0bea23bfd9"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Advise patients that if eye inflammation or pain persists longer than 48 hours or becomes aggravated, they should consult a physician.</paragraph>
                        <paragraph>Advise patients that to prevent eye injury or contamination, care should be taken to avoid touching the bottle tip to eyelids or to any other surface. The use of this bottle by more than one person may spread infection. Keep bottle tightly closed when not in use. Keep out of the reach of children.</paragraph>
                        <paragraph>Advise patients that prednisolone acetate ophthalmic suspension contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of prednisolone acetate ophthalmic suspension and may be reinserted 15 minutes following its administration.</paragraph>
                     </text>
                     <effectiveTime value="20220405"/>
                  </section>
               </component>
               <component>
                  <section ID="ID18">
                     <id root="f12bc570-315f-4d09-a8bd-3475e2c3b3c9"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No studies have been conducted in animals or in humans to evaluate the potential of these effects.</paragraph>
                     </text>
                     <effectiveTime value="20220405"/>
                  </section>
               </component>
               <component>
                  <section ID="ID20">
                     <id root="1f641271-0038-4395-bf39-36326db3ecaf"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph>Prednisolone has been shown to be teratogenic in mice when given in doses 1 to 10 times the human dose. Dexamethasone, hydrocortisone, and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation. A significant increase in the incidence of cleft palate was observed in the fetuses of the treated mice. There are no adequate well-controlled studies in pregnant women. Prednisolone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20220405"/>
                  </section>
               </component>
               <component>
                  <section ID="ID22">
                     <id root="c4d8b5d5-c521-4974-ab79-a179e4a1ff26"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from prednisolone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20220405"/>
                  </section>
               </component>
               <component>
                  <section ID="ID24">
                     <id root="8dde1c4a-55a4-4bd4-9149-ed99e90e36c3"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness in pediatric patients have been established. Use in pediatric patients is supported by evidence from adequate and well-controlled studies of prednisolone acetate ophthalmic suspension in adults with additional data in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20220405"/>
                  </section>
               </component>
               <component>
                  <section ID="ID26">
                     <id root="4def9017-ed19-4513-a7db-5d1d07c45c4c"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20220405"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID28">
               <id root="facb7dae-47ea-4e79-a4c5-28ce19170c97"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions have been identified during use of Prednisolone acetate ophthalmic suspension. Because reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                  <paragraph>Adverse reactions include elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing.</paragraph>
                  <paragraph>The development of secondary ocular infection (bacterial, fungal, and viral) has occurred. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion should be considered in any persistent corneal ulceration where steroid treatment has been used (<content styleCode="italics">see <linkHtml href="#ID15">PRECAUTIONS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>Other adverse reactions reported with the use of prednisolone acetate ophthalmic suspension include: allergic reactions; dysgeusia; eye pain; foreign body sensation; headache; pruritus; rash; transient burning and stinging upon instillation and other minor symptoms of ocular irritation; urticaria; and visual disturbance (blurry vision).</paragraph>
                  <paragraph>Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. Corticosteroid-containing preparations have also been reported to cause acute anterior uveitis and perforation of the globe.</paragraph>
                  <paragraph>To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</paragraph>
               </text>
               <effectiveTime value="20220405"/>
            </section>
         </component>
         <component>
            <section ID="ID30">
               <id root="a49cf019-6894-4fb7-b4b4-ab03cfe61243"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute.</paragraph>
               </text>
               <effectiveTime value="20220405"/>
            </section>
         </component>
         <component>
            <section ID="ID32">
               <id root="66104c51-e096-4312-8e0a-4a31ada5ada5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Shake well before using. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.</paragraph>
                  <paragraph>If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated (<content styleCode="italics">see <linkHtml href="#ID15">PRECAUTIONS</linkHtml>
                     </content>).</paragraph>
               </text>
               <effectiveTime value="20220405"/>
            </section>
         </component>
         <component>
            <section ID="ID34">
               <id root="4eb901b9-bf1b-4356-a674-882e66806b4c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Product:    50090-7539</paragraph>
                  <paragraph>NDC:    50090-7539-0   5 mL in a BOTTLE  /  1  in a  CARTON </paragraph>
               </text>
               <effectiveTime value="20250424"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e8af0abd-6dc2-4ff1-97b7-c7dd51fd801f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>prednisolone acetate</title>
               <text>
                  <renderMultiMedia referencedObject="lbl500907539"/>
               </text>
               <effectiveTime value="20250424"/>
               <component>
                  <observationMedia ID="lbl500907539">
                     <text>Label Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl500907539.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>